Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of CAR-T cell therapy in chronic lymphocytic leukemia: A meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CVCharan Thej Reddy VegivintiSPSivaguha Yadunath PrabhakaranAMA. W. McMillen

Discussion

Loading...

Member takes

Overview

Meta-analysis demonstrates 60.8% overall response rate in CLL patients treated with CAR-T therapy, indicating moderate efficacy.

Key Points

  • This meta-analysis evaluates the efficacy of CAR-T cell therapy in treating Chronic Lymphocytic Leukemia (CLL).
  • Systematic literature search conducted to identify clinical trials for CAR-T cell therapies in CLL.
  • 6 studies including 4 clinical trials and 2 ASH abstracts were analyzed.
  • Random-effect models used to report outcomes such as overall response rate and median survival metrics.
  • Overall response rate (ORR) pooled at 60.8% with variability between studies.
  • Complete response (CR) pooled at 28.8%, indicating significant heterogeneity.
  • Pooled minimal residual disease (MRD) negativity rate at 70.8%, showing promise in treatment outcomes.

Cite This Study

Vegivinti et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0c8https://doi.org/10.1182/blood-2025-2740
View Full Paper
Ask AI
Bookmark
Share